RxDoctor Payments Data

Peter Panton, MD

Ophthalmology · Elmwood Park, ILNPI 1063401784

Payments from drug & device makers

$1,676in general payments, 2019–2025

Across 23 payments — averaging $72.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$817
  • AbbVie$210
  • Johnson & Johnson Surgical Vision, Inc.$195
  • Amgen$141
  • Bausch & Lomb Americas Inc.$113
  • Carl Zeiss Meditec USA, Inc.$87
  • plus $113 from 3 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$1,54592%
  • Education$744%
  • Gifts$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,676 in reported general payments places this provider in the 50th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$290,121
Medicare patients
702
Services billed
2,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost44$18,804
SimbrinzaBrinzolamide/Brimonidine Tart46$9,820
Travoprost21$5,769
Alphagan PBrimonidine Tartrate13$5,303
CombiganBrimonidine Tartrate/Timolol19$4,228
Prednisolone Acetate80$3,162
Latanoprost303$2,965
Loteprednol Etabonate11$2,400
Timolol Maleate146$1,504
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat77$1,146
Tobramycin-DexamethasoneTobramycin/Dexamethasone22$1,023
Ketorolac Tromethamine19$352
Brimonidine Tartrate23$307
Cephalexin16$230
Levobunolol Hcl18$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan$210$28,33676 claims
AlconSimbrinza$817$9,82046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Elmwood Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →